

UNITED STATES (C) RECEIV SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

NOTICE OF SALE OF SECT PURSUANT TO REGULATI **SECTION 4(6), AND/OR**

	OWR	A٢	PKO	VAL
MR	Num	har		323

35-0076 Expires: May 31, 2005

Èstimated average burden hours per response. 16.00

SEC USE ONLY					
Serial 					
CEIVED					

Name of Offering (check if this is an amendment and name has changed, and indicate change.)	ffering of Common Stock and Series A Preferred
Stock for aggregate offering of up to \$750,000	
Filing Under (Check box(es) that apply): Rule 504 Rule 505 Rule 506 Section 4(e	6) ULOE
Type of Filing: New Filing Amendment	
A. BASIC IDENTIFICATION DATA	
1. Enter the information requested about the issuer	
Name of Issuer (check if this is an amendment and name has changed, and indicate change.)	
Solaribus Biomedical Corporation	
Address of Executive Offices (Number and Street, City, State, Zip Code)	Telephone Number (Including Area Code)
100 Rialto Place, Suite 700, Melbourne, FL 32901	321-726-9200
Address of Principal Business Operations (Number and Street, City, State, Zip Code) (if different from Executive Offices)	Telephone Number (Including Area Code)
Brief Description of Business	CARE
Development and use of hyperspectral imaging techniques and sensors.	PROCESSED FEB 20 2004
Type of Business Organization	EFB 20 2004
business trust limited partnership, to be formed	THOMSON
Month Year	File-area
Actual or Estimated Date of Incorporation or Organization: 08 03 Actual Es Jurisdiction of Incorporation or Organization: (Enter two-letter U.S. Postal Service abbreviation for Sta	timated ite:
CN for Canada; FN for other foreign jurisdiction)	F[L]

GENERAL INSTRUCTIONS

Federal:

Who Must File: All issuers making an offering of securities in reliance on an exemption under Regulation D or Section 4(6), 17 CFR 230.501 et seq. or 15 U.S.C. 77d(6).

When To File: A notice must be filed no later than 15 days after the first sale of securities in the offering. A notice is deemed filed with the U.S. Securities and Exchange Commission (SEC) on the earlier of the date it is received by the SEC at the address given below or, if received at that address after the date on which it is due, on the date it was mailed by United States registered or certified mail to that address.

Where To File: U.S. Securities and Exchange Commission, 450 Fifth Street, N.W., Washington, D.C. 20549.

Copies Required: Five (5) copies of this notice must be filed with the SEC, one of which must be manually signed. Any copies not manually signed must be photocopies of the manually signed copy or bear typed or printed signatures.

Information Required: A new filing must contain all information requested. Amendments need only report the name of the issuer and offering, any changes thereto, the information requested in Part C, and any material changes from the information previously supplied in Parts A and B. Part E and the Appendix need not be filed with the SEC.

Filing Fee: There is no federal filing fee.

This notice shall be used to indicate reliance on the Uniform Limited Offering Exemption (ULOE) for sales of securities in those states that have adopted ULOE and that have adopted this form. Issuers relying on ULOE must file a separate notice with the Securities Administrator in each state where sales are to be, or have been made. If a state requires the payment of a fee as a precondition to the claim for the exemption, a fee in the proper amount shall accompany this form. This notice shall be filed in the appropriate states in accordance with state law. The Appendix to the notice constitutes a part of this notice and must be completed.

ATTENTION-

Failure to file notice in the appropriate states will not result in a loss of the federal exemption. Conversely, failure to file the appropriate federal notice will not result in a loss of an available state exemption unless such exemption is predictated on the filing of a federal notice.

		A. BASIC II	DENTIFICATION DATA		
2. Enter the information re	equested for the fo	llowing:	2000 AND COLUMN TO THE COLUMN	September 1997	
	•	_	within the past five years;		
•	,	•	• • •	n of 10% or more of	a class of equity securities of the issuer
		•	•		• •
		•	of corporate general and ma	maging partners of	partnership issuers; and
Each general and in the second s	managing partner o	of partnership issuers.			
Check Box(es) that Apply:	Promoter	Beneficial Owner	Executive Officer	✓ Director	General and/or Managing Partner
Full Name (Last name first,	if individual)		· ·		
Mazzocchi, Rudy					
Business or Residence Addre	ess (Number and	Street, City, State, Zip (Code)		
c/o Solaribus Biomedical	Corporation, 100	Rialto Place, Suite 70	0, Melbourne, FL 32901		
Check Box(es) that Apply:	Promoter	Beneficial Owner	Executive Officer	Director	General and/or Managing Partner
Full Name (Last name first,	if individual)				
Barnes, Donald Michael	,				
Business or Residence Addre	ess (Number and	Street, City, State, Zip (Code)		
c/o Solaribus Biomedical		•			
Check Box(es) that Apply:	Promoter	Beneficial Owner	·	✓ Director	General and/or Managing Partner
Full Name (Last name first, Adams, Scott H.	if individual)	<u></u>			
	Olumbar and	Street, City, State, Zip (7.4.		
Business or Residence Addre	•		•		·
c/o Solaribus Biomedical					
Check Box(es) that Apply:	Promoter	Beneficial Owner	Executive Officer	☑ Director	General and/or Managing Partner
Full Name (Last name first, Wasserman, Herbert M.	if individual)				
		St C': St 7: .			
Business or Residence Addre		Street, City, State, Zip C			•
c/o Solaribus Biomedical	Corporation, 100				
Check Box(es) that Apply:	Promoter	Beneficial Owner	Executive Officer	Director	General and/or Managing Partner
Full Name (Last name first,	if individual)				
Cenetec LLC					
Business or Residence Addre	ess (Number and	Street, City, State, Zip C	Code)		
4950 Communication Ave	nue, Suite 900, B	oca Raton, FL 33431			
Check Box(es) that Apply:	Promoter	Beneficial Owner	Executive Officer	Director	General and/or Managing Partner
Full Name (Last name first, i	if individual)				
Galileo Group, Inc.					
Business or Residence Addre	ss (Number and	Street, City, State, Zip C	Code)		
100 Rialto Place, Suite 73	37, Melbourne, FL	. 32901			
Check Box(es) that Apply:	Promoter	Beneficial Owner	Executive Officer	Director	General and/or Managing Partner
Full Name (Last name first, i	if individual)				
Business or Residence Addre	ess (Number and	Street, City, State, Zip C	Code)		
c/o Solaribus Biomedical	•		•		

					B. 11	NFORMAT	ION ABOU	T OFFERI	NG.				
1.	Use the issuer sold, or done the issuer intend to sall, to non-governited investors in this offering?							Yes	No				
1.	Has the issuer sold, or does the issuer intend to sell, to non-accredited investors in this offering?						•••••		Ø				
2.	What is the minimum investment that will be accepted from any individual?							\$_N/A					
												Yes	No
3.			permit joint									✓.	
4. Enter the information requested for each person who has been or will be paid or given, directly or indirectly, any commission or similar remuneration for solicitation of purchasers in connection with sales of securities in the offering If a person to be listed is an associated person or agent of a broker or dealer registered with the SEC and/or with a state or states, list the name of the broker or dealer. If more than five (5) persons to be listed are associated persons of such a broker or dealer, you may set forth the information for that broker or dealer only.							:						
Ful N/		Last name	first, if indi	vidual)			-						
		Residence	Address (N	umber and	l Street, Ci	ty, State, Z	(ip Code)						
Nar	me of As	sociated Br	oker or Dea	aler									
Sta	tes in Wh	ich Person	Listed Has	Solicited	or Intends	to Solicit	Purchasers		<u></u>				
	(Check	"All States	or check	individual	States)		***************************************			***************************************		All States	
	AL IL MT RI	AK IN NE SC	IA NV SD	AR KS NII TN	CA KY NJ TX	CO LA NM UT	CT ME NY VT	DE MD NC VA	DC MA ND WA	MI OII WV	GA MN OK WI	MS OR WY	MO PA PR
Ful	l Name (Last name	first, if indi	vidual)									
Bus	siness of	Residence	Address (1	Number an	d Street, C	ity, State,	Zip Code)						
Nai	me of As	sociated Bi	oker or De	aler									<u></u>
Sta	tes in WI	nich Persor	Listed Has	Solicited	or Intends	to Solicit	Purchasers						
	(Check	"All States	s" or check	individual	States)	***************				***************		☐ AI	l States
	AL IL MT RI	AK IN NE SC	IA NV SD	AR KS NH TN	CA KY NJ TX	LA NM UT	ME NY VT	MD NC VA	DC MA ND WA	FL MI OH WV	GA MN OK WI	HI MS OR WY	MO PA PR
Ful	ll Name (Last name	first, if ind	ividual)			<u> </u>			······································			
Bus	siness or	Residence	: Address (1	Number an	d Street, C	City, State,	Zip Code)						
Name of Associated Broker or Dealer													
States in Which Person Listed Has Solicited or Intends to Solicit Purchasers													
(Check "All States" or check individual States)								☐ Ai	l States				
	AL IL MT RI	AK IN NE SC	AZ IA NV SD	AR KS NH TN	CA KY NJ TX	CO LA NM UT	ME NY VT	DE MD NC VA	DC MA ND WA	FL MI OH WV	GA MN OK WI	HI MS OR WY	MO PA PR

C. OFFERING PRICE, NUMBER OF INVESTORS, EXPENSES AND USE OF PROCEEDS

	sold. Enter "0" if the answer is "none" or "zero." If the transaction is an exchange offering, check this box \square and indicate in the columns below the amounts of the securities offered for exchange and already exchanged.	Aggregate	Amount Already
	Type of Security	Offering Price	Sold
	Debt	-0-	\$ -0-
	Equity	750,000	§ 95,000
	Convertible Securities (including warrants)	g -0-	\$ -0-
	Partnership Interests		\$ -0 -
	Other (Specify)		\$ -0
	Total		\$ 95,000
	Answer also in Appendix, Column 3, if filing under ULOE.		
	Enter the number of accredited and non-accredited investors who have purchased securities in this offering and the aggregate dollar amounts of their purchases. For offerings under Rule 504, indicate the number of persons who have purchased securities and the aggregate dollar amount of their purchases on the total lines. Enter "0" if answer is "none" or "zero."	Number	Aggregate Dollar Amount
		Investors	of Purchases
	Accredited Investors		§ 95,000
	Non-accredited Investors		\$
	Total (for filings under Rule 504 only)		\$
	Answer also in Appendix, Column 4, if filing under ULOE.		
3.	If this filing is for an offering under Rule 504 or 505, enter the information requested for all securities sold by the issuer, to date, in offerings of the types indicated, in the twelve (12) months prior to the first sale of securities in this offering. Classify securities by type listed in Part C — Question 1.		
•		Type of	Dollar Amount
	Type of Offering	Security	Sold
	Rule 505		\$
	Regulation A		\$
	Rule 504		\$
	Total		\$
4	a. Furnish a statement of all expenses in connection with the issuance and distribution of the securities in this offering. Exclude amounts relating solely to organization expenses of the insurer. The information may be given as subject to future contingencies. If the amount of an expenditure is not known, furnish an estimate and check the box to the left of the estimate.		
	Transfer Agent's Fees] \$
	Printing and Engraving Costs] \$
	Legal Fees		\$ 30,000
	Accounting Fees] \$
	Engineering Fees] \$
	Sales Commissions (specify finders' fees separately)] \$
	Other Expenses (identify)] \$
	Total		\$ 30,000

	C. OFFERING PRICE, NUMI	BER OF INVESTORS, EXPENSES AND USE OF PI	ROCEEDS				
	b. Enter the difference between the aggregate offering price given in response to Part C — Question 1 and total expenses furnished in response to Part C — Question 4.a. This difference is the "adjusted gross proceeds to the issuer."						
5.	Indicate below the amount of the adjusted gross pro each of the purposes shown. If the amount for an check the box to the left of the estimate. The total of proceeds to the issuer set forth in response to Part						
			Payments to Officers, Directors, & Affiliates	Payments to Others			
	Salaries and fees		7\$. \$			
	Purchase of real estate	_	="	 -			
	Purchase, rental or leasing and installation of mac and equipment						
	Construction or leasing of plant buildings and fac-	- ilities	¬\$	 			
	Acquisition of other businesses (including the val- offering that may be used in exchange for the asse issuer pursuant to a merger)	7\$	— □\$				
	Repayment of indebtedness	-	· ···				
	Working capital	_					
	Other (specify):		-	_			
] \$	\$			
	Column Totals] \$	720,000			
	Total Payments Listed (column totals added)		 \$ 5 7 1	20,000			
Γ		D. FEDERAL SIGNATURE					
sig	e issuer has duly caused this notice to be signed by the nature constitutes an undertaking by the issuer to fur information furnished by the issuer to any non-acc	nish to the U.S. Securities and Exchange Commiss	sion, upon writte				
Iss	uer (Print or Type)	Signature	ate				
Solaribus Biomedical Corporation		Herbert W. Wasserran	February /3	, 2004			
Na	me of Signer (Print or Type)	Title of Signer (Print or Type)					
Н	erbert M. Wasserman	Secretary and Treasurer					